Award

Kahn honored for research, mentoring

She won FASEB's Excellence in Science Award
George Van Den Driessche
By George Van Den Driessche
April 01, 2019

Barbara Kahn is the recipient of the Federation of American Societies for Experimental Biology’s 2019 Excellence in Science Award.

Barbara Kahn
“It is an honor to receive this award on behalf of the talented postdoctoral fellows, students and junior faculty who have catalyzed the discoveries in my lab, and our collaborators who have expanded our scientific horizons. The inspiration and skills of this team deserve this award. As a physician-scientist, my vision is to leverage emerging technologies to better understand metabolism and discover new approaches to prevent and treat metabolic diseases.”

— BARBARA KAHN

FASEB is honoring Kahn, the George R. Minot endowed chair and professor of medicine at Harvard Medical School and vice chair for research strategy in the Beth Israel Deaconess Medical Center department of medicine, for her contributions to diabetes research and the scientific community. Kahn is a member of the National Academy of Sciences and the National Academy of Medicine and a fellow of the American Association for the Advancement of Science.

Gerald I. Shulman, a professor at Yale University, wrote in his nomination letter that Kahn “has made pioneering discoveries throughout the past 30 years that elucidate the molecular mechanisms underlying obesity, insulin resistance and type 2 diabetes, with a particular emphasis on the role of the adipocyte in regulating glucose homeostasis.”

In the 1990s, Kahn discovered that obese and diabetic people had downregulation of the major insulin-regulated glucose transporter protein, GLUT4, in fat cells, causing insulin resistance. This discovery fueled a research career studying insulin action and the pathogenesis of type 2 diabetes. Kahn’s work regarding the cellular and molecular effects of altered GLUT4 levels resulted in identification of novel mechanisms that cause insulin resistance and increase the risk of developing diabetes. In the early 2000s, her lab determined that the fat-secreted retinol binding protein 4, RBP4, is increased in adipose tissue and blood in obesity and type 2 diabetes in humans, and this causes insulin resistance by creating a pro-inflammatory state. In 2012, Kahn’s lab found that increasing GLUT4 protein expression induces carbohydrate-response element-binding protein (ChREBP) which regulates fatty acid synthesis. Kahn’s lab discovered ChREBP is necessary in adipocytes to maintain whole-body insulin sensitivity.

The insights gained from these studies led to the discovery of a new class of lipids called branched fatty acid hydroxy fatty acids, or FAHFAs. Insulin-resistant people have low biological concentrations of FAHFAs. If these lipids are restored to normal healthy levels in diabetic mice, insulin sensitivity improves. These lipids may provide a new therapeutic treatment for Type 2 diabetes.

Kahn’s contributions go beyond groundbreaking research. She has mentored 100 postdocs and students, and she has played a leadership role in mentoring programs that help junior faculty, especially underrepresented minorities and women, gain high-visibility positions in the research community.

As a physician–researcher, Kahn has served as a consultant for the National Diabetes Advisory Board at the National Institutes of Health and is on the Advisory Council for the National Institute of Diabetes, Digestive and Kidney Diseases. She has served on numerous American Diabetes Association committees and as an editor for several academic journals. Kahn is also a leader within the Beth Israel Deaconess Medical Center where she was chief of the Diabetes Unit and the Division of Endocrinology, Diabetes, and Metabolism. She also co-chairs the Unconscious Bias Awareness committee for the department’s Committee on the Advancement of Women.

Kahn will receive her award at the ASBMB annual meeting during the Experimental Biology 2019 conference in Orlando, where she will deliver an award lecture titled “Glucose transport, adipose biology and novel mechanisms for regulating systemic insulin sensitivity” at 8 a.m. April 8 in Valencia Ballroom A at the Orange County Convention Center.

George Van Den Driessche
George Van Den Driessche

George Van Den Driessche is a Ph.D. student in chemistry at North Carolina State University. Follow him on Twitter.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in People

People highlights or most popular articles

'Every experiment and every breakthrough matters'
Health Observance

'Every experiment and every breakthrough matters'

February 26, 2021

An interview with NYMC dean Marina K. Holz, who studies a rare disease that affects women of childbearing age.

Connecting chemistry with education
Jobs

Connecting chemistry with education

February 26, 2021

Meet Christiane Stachl, director of education, outreach and diversity at Center for Genetically Encoded Materials at UC Berkeley.

Raising awareness and funding for Pompe disease
Health Observance

Raising awareness and funding for Pompe disease

February 25, 2021

Father-turned-advocate has founded multiple organizations to support families and search for better therapies for people with rare lysosomal storage disorder.

Tributes to Barbara Gordon, ASBMB executive director, on her retirement
Stroopwafels

Tributes to Barbara Gordon, ASBMB executive director, on her retirement

February 24, 2021

Society members and former staff share their appreciation and memories of Gordon who worked at the American Society for Biochemistry and Molecular Biology for almost 50 years.

Booker edits new journal; Bumpus featured in virtual museum
Member News

Booker edits new journal; Bumpus featured in virtual museum

February 22, 2021

Awards, promotions, milestones and more. Find out what's going on in the lives of ASBMB members.

Remembering Kanfer and Barry
In Memoriam

Remembering Kanfer and Barry

February 22, 2021

Julian Kanfer was one of the first researchers to study the link between amyloid ß protein and Alzheimer’s disease. Bridgette Barry focused on how the dynamic protein matrix facilitates enzyme-based catalysis.